Sabon Salo 2019 3-Aminopyrazine-2-Carboxylic Acid CAS Lamba 5424-01-1

Haƙiƙa ɗimbin abubuwan gudanar da ayyukan gudanarwa da ƙirar mai ba da hanya ɗaya zuwa ɗaya kawai suna ba da mahimmancin mahimmancin sadarwar ƙungiyar da sauƙin fahimtar abubuwan da kuke tsammanin don 2019 Sabon Salo 3-Aminopyrazine-2-Carboxylic Acid CAS No. 5424-01-1, Mu suna shirye su ba ku mafi ƙarancin farashi a kasuwa, mafi kyawun inganci da sabis na tallace-tallace mai kyau. Barka da zuwa yin bussines tare da mu, bari mu zama nasara biyu.
Haƙiƙa ƙwararrun ayyukan gudanarwa da yawa da ƙirar mai samarwa ɗaya zuwa ɗaya suna ba da mahimmancin mahimmancin sadarwar ƙungiya da sauƙin fahimtar abubuwan da kuke tsammanin donChina 3-Aminopyrazine-2-Carboxylic Acid da 5424-01-1, Kayayyakinmu sun shahara sosai a cikin kalmar, kamar Kudancin Amurka, Afirka, Asiya da sauransu.Kamfanoni don "ƙirƙirar samfurori na farko" a matsayin makasudin, kuma suna ƙoƙari su ba abokan ciniki tare da ingantattun mafita, samar da sabis na tallace-tallace mai inganci da goyon bayan fasaha, da fa'idar abokin ciniki, ƙirƙirar kyakkyawan aiki da gaba!

2'-Methoxy-3'-nitro-biphenyl-3-carboxylic acid ana amfani dashi azaman matsakaici na Eltrombopag.
Eltrombopag, wanda GlaxoSmithKline (GSK) ya haɓaka a Burtaniya kuma daga baya aka haɓaka tare da Novartis a Switzerland, shine farkon kuma kawai wanda aka amince da ƙananan ƙwayoyin cuta marasa peptide TPO agonist a duniya.An amince da Eltrombopag ta FDA ta Amurka a cikin 2008 don maganin cututtukan thrombocytopenic purpura (ITP), kuma a cikin 2014 don maganin anemia mai tsanani (AA).Hakanan shine magani na farko da FDA ta Amurka ta amince don maganin AA a cikin shekaru 30 na baya-bayan nan.
A cikin Disamba 2012, FDA ta Amurka ta amince da Eltrombopag don maganin thrombocytopenia a cikin marasa lafiya tare da ciwon hanta na kullum C (CHC), don haka marasa lafiya na hepatitis C tare da rashin jin dadi saboda ƙananan platelet zasu iya farawa da kuma kula da interferon bisa daidaitattun maganin cututtuka na hanta.A ranar 3 ga Fabrairu, 2014, GlaxoSmithKline ya sanar da cewa FDA ta ba da nasarar cancantar maganin miyagun ƙwayoyi na Eltrombopag don maganin hemopenia a cikin marasa lafiya tare da anemia mai tsanani na sinadarai (SAA) waɗanda ba su da cikakkiyar amsa ga immunotherapy.A ranar 24 ga Agusta, 2015, FDA ta Amurka ta amince da Eltrombopag don maganin thrombocytopenia a cikin manya da yara masu shekaru 1 da haihuwa tare da thrombocytopenia na rigakafi na yau da kullum (ITP) waɗanda basu da isasshen amsa ga corticosteroids, immunoglobulins ko splenectomy.A ranar 4 ga Janairu, 2018, an amince da Eltrombopag da za a jera shi a kasar Sin don maganin thrombocytopenia na rigakafi na farko (ITP).

Haƙiƙa ɗimbin abubuwan gudanar da ayyukan gudanarwa da ƙirar mai ba da hanya ɗaya zuwa ɗaya kawai suna ba da mahimmancin mahimmancin sadarwar ƙungiyar da sauƙin fahimtar abubuwan da kuke tsammanin don 2019 Sabon Salo 3-Aminopyrazine-2-Carboxylic Acid CAS No. 5424-01-1, Mu suna shirye su ba ku mafi ƙarancin farashi a kasuwa, mafi kyawun inganci da sabis na tallace-tallace mai kyau. Barka da zuwa yin bussines tare da mu, bari mu zama nasara biyu.
2019 Sabon SaloChina 3-Aminopyrazine-2-Carboxylic Acid da 5424-01-1, Kayayyakinmu sun shahara sosai a cikin kalmar, kamar Kudancin Amurka, Afirka, Asiya da sauransu.Kamfanoni don "ƙirƙirar samfurori na farko" a matsayin makasudin, kuma suna ƙoƙari su ba abokan ciniki tare da ingantattun mafita, samar da sabis na tallace-tallace mai inganci da goyon bayan fasaha, da fa'idar abokin ciniki, ƙirƙirar kyakkyawan aiki da gaba!